Recruiting soon

Aspirin Dosage Comparison for Preeclampsia Prevention in High-Risk Pregnancies

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study observes if different aspirin dosages can prevent preeclampsia in high-risk pregnancies, tracking both early and late onset of the condition.

What is being tested

Aspirin 75 mg

+ Aspirin 150 mg

Drug
Who is being recruted

Urogenital Diseases+2

+ Female Urogenital Diseases and Pregnancy Complications

+ Pre-Eclampsia

From 18 to 30 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Interventional
Study Start: November 2025
See protocol details

Summary

Principal SponsorShalamar Hospital
Study ContactDr. Hafiz Wajahat Naseem Naseem, M.B.B.S
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2025

Actual date on which the first participant was enrolled.

This study focuses on finding the best dose of Aspirin to help prevent pre-eclampsia in pregnant women who are at high risk for this condition. Pre-eclampsia is a serious condition that can affect both the mother and the baby, potentially leading to complications during pregnancy. It occurs in 5-7% of all pregnancies and can be life-threatening. Aspirin is known to help prevent pre-eclampsia by improving blood flow to the placenta and reducing inflammation and blood clot formation. This study aims to compare two different doses of Aspirin, 75mg and 150mg, to see which is more effective in the Pakistani population, as different guidelines exist on the appropriate dose for prevention of pre-eclampsia. Participants in this study will take either 75mg or 150mg of Aspirin daily from early in their pregnancy, starting at 12 weeks. Researchers will monitor the participants to see if they develop pre-eclampsia, and if so, whether it occurs early or later in the pregnancy. The outcomes will be measured by checking whether pre-eclampsia develops before or after 34 weeks of pregnancy. The study will help determine if a higher dose of Aspirin is more effective in preventing pre-eclampsia, potentially leading to improved care for pregnant women at risk of this condition. The main focus is on assessing whether the benefits of preventing pre-eclampsia outweigh any potential side effects of taking a higher dose of Aspirin.

Official TitleComparing the Efficacy of 75mg Versus 150mg Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women
NCT07041385
Principal SponsorShalamar Hospital
Study ContactDr. Hafiz Wajahat Naseem Naseem, M.B.B.S
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

340 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 30 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsPre-EclampsiaPregnancy ComplicationsHypertension, Pregnancy-Induced

Criteria

5 inclusion criteria required to participate
Screen positive women

Age 18 - 30 y

Gestational Age 11 - 13+6 weeks

Singleton Pregnancy

Show More Criteria

5 exclusion criteria prevent from participating
Screen negative women

Age > 30 y

Gestational Age > 14 weeks

Multiple Gestation

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Group A: 75 mg aspirin nightly.

Group II

Experimental
Group B: 150 mg aspirin nightly.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Shalamar Hospital

Lahore, PakistanOpen Shalamar Hospital in Google Maps
Recruiting soonOne Study Center